D
Devraj Pamoorthy Srinivasan
Publications - 6
Citations - 986
Devraj Pamoorthy Srinivasan is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications receiving 578 citations.
Papers
More filters
Journal ArticleDOI
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E.W. Cohen,Denis Soulières,Christophe Le Tourneau,Christophe Le Tourneau,Christophe Le Tourneau,José Dinis,Lisa Licitra,Myung-Ju Ahn,Ainara Soria,Jean-Pascal Machiels,Jean-Pascal Machiels,Nicolas Mach,Ranee Mehra,Barbara Burtness,Pingye Zhang,Jonathan D. Cheng,Ramona F. Swaby,Kevin J. Harrington,Kevin J. Harrington,Mirelis Acosta-Rivera,Douglas Adkins,Morteza Aghmesheh,Mario Airoldi,Eduardas Aleknavicius,Yousuf Al-Farhat,Alain Algazi,Salah Almokadem,Anna Alyasova,Jessica Bauman,Marco Benasso,Alfonso Berrocal,Victoria Bray,Barbara Ann Burtness,F. Caponigro,Ana Castro,Terrence P. Cescon,Kelvin K. W. Chan,Arvind Chaudhry,Bruno Chauffert,Ezra W. Cohen,Tibor Csoszi,J. de Boer,Jean-Pierre Delord,Andreas Dietz,Charlotte Dupuis,Laurence Digue,Jozsef Erfan,Yolanda Alvarez,Mererid Evans,Mary J. Fidler,Martin David Forster,Signe Friesland,Apar Kishor Ganti,Lionnel Geoffrois,Cliona Grant,Viktor Gruenwald,Kevin J. Harrington,Thomas K. Hoffmann,Geza Horvai,Arturas Inciura,Raymond Woo-Jun Jang,Petra Jankowska,Antonio Jimeno,Mano Joseph,Alejandro Juarez Ramiro,Boguslawa Karaszewska,Andrzej Kawecki,Ulrich Keilholz,Ulrich Keller,Sung Bae Kim,Judit Kocsis,Nuria Kotecki,Mark F. Kozloff,Julio Lambea,Laszlo Landherr,Yuri Lantsukhay,Sergey Alexandrovich Lazarev,Lip Way Lee,Igor Dmitrievich Lifirenko,Danko Martincic,Oleg Vladmirovhich Matorin,Margaret McGrath,Krzysztof Misiukiewicz,John C. Morris,Fagim Fanisovich Mufazalov,Jiaxin Niu,Devraj Pamoorthy Srinivasan,Pedro Perez Segura,Daniel Rauch,Maria Leonor Ribeiro,Cristina P. Rodriguez,Frederic Rolland,Antonio Russo,Agnes Ruzsa,Frederico Sanches,Sang-Won Shin,Mikhail Shtiveland,Pol Specenier,Eva Szekanecz,Judit Szota,Carla M.L. van Herpen,Hector A. Velez-Cortes,William V. Walsh,Stefan Wilop,Ralph Winterhalder,Marek Z. Wojtukiewicz,Deborah Wong,Dan P. Zandberg +107 more
TL;DR: The clinically meaningful prolongation of overall survival and favourable safety profile of pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma support the further evaluation of p embrolizUMab as a monotherapy and as part of combination therapy in earlier stages of disease.
Journal ArticleDOI
Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial.
Christopher M. Nutting,Laura Finneran,Justin W. G. Roe,M. Sydenham,Matthew Beasley,Shreerang Bhide,Cheng Boon,Audrey Cook,E. De Winton,M. Emson,Bernadette Foran,Robert Frogley,Imran Petkar,Laura Pettit,Keith Rooney,Tom Roques,Devraj Pamoorthy Srinivasan,Justine Tyler,Emma Hall +18 more
Journal ArticleDOI
Neoadjuvant tyrosine kinase inhibitor therapy in locally advanced differentiated thyroid cancer: a single centre case series.
Jjy Yeo,Kirsten E. Stewart,Pavithran Maniam,S B Arman,Devraj Pamoorthy Srinivasan,Lucy Wall,Morna MacNeill,Mwj Strachan,Iain J. Nixon +8 more
Posted ContentDOI
Association between immune-related adverse events and clinical outcomes for head and neck squamous cell carcinoma treated with first-line palliative pembrolizumab monotherapy or in combination with chemotherapy: a national, multi-centre, real-world, retrospective cohort study
Ashish Thapa,Alissa Cowell,Anthea Peters,Arthur D. James,CW Lamb,Derek Grose,Seema Vohra,S. Schipani,Karen Mactier,J. Mackenzie,Douglas J Noble,Devraj Pamoorthy Srinivasan,Kirsten Laws,Rafael Moleron,Paddy Niblock,Feng-Yi Soh,Claire Paterson,C. Wilson +17 more
TL;DR: In this paper , the authors provided real-world performance data and identified clinical factors associated with survival outcomes for patients receiving first-line pembrolizumab-containing treatment for head and neck squamous cell carcinoma (HNSCC) in the palliative setting.
Journal ArticleDOI
Opsoclonus-myoclonus paraneoplastic syndrome in nasopharyngeal carcinoma
TL;DR: This case adds to a small but growing body of literature related to anti-Ri antibodies, opsoclonus-myOClonus syndrome presentations, and is the first reported association of this combination with nasopharyngeal carcinoma.